CSL Ltd Income Statement Analysis
ASX:CSL
Health Care
•
Biotechnology
Income Statement
Comprehensive analysis of CSL Ltd's revenue, expenses, and profitability
| Items | 2024 | 2025 | |
|---|---|---|---|
| Revenue | |||
| Total Revenue | 14.7B | 15.4B | |
| Costs and Expenses | |||
| Cost of Revenue | (7.1B) | (7.5B) | |
| Gross Profit | 7.6B | 8.0B | |
| Operating Expenses | (4.8B) | (5.0B) | |
| Operating Income | 2.8B | 3.0B | |
| Other Income/Expenses | |||
| Interest Expense | (420M) | (393M) | |
| Profit Before Taxes | 3.4B | 3.7B | |
| Income Tax | 661M | 588M | |
| Net Income | 2.6B | 3.0B | |
| Per Share Data | |||
| Basic EPS | 5.47 | 6.2 | |
| Diluted EPS | 5.45 | 6.18 | |
| Shares Outstanding (in millions) | |||
| Basic Shares | 483M | 484M | |
| Diluted Shares | 485M | 486M | |
Note: Fiscal year ends in June. All amounts are in AUD millions except per share data. Negative values are shown in parentheses and colored red. EPS values are shown to 3 decimal places, share counts are simplified (M = millions, B = billions).